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Abstract
Background: The role of metabolic syndrome (MetS) in prostate cancer risk is still debated. We investigated it in a
large population-based case–control study.
Methods: Cases were 1937 men with incident prostate cancer, aged ≤75 years, diagnosed across French hospitals
in the Montreal area between 2005 and 2009. Concurrently, 1995 population controls from the same residential
area and age distribution were randomly selected from electoral list of French-speaking men. Detailed lifestyle and
medical histories, and anthropometric measures, were collected during in-person interviews. Prevalence of MetS
components (type 2 diabetes, high blood pressure, dyslipidemia and abdominal obesity) was estimated at 2 years
before diagnosis for cases/ interview for controls, and at ages 20, 40, 50 and 60. Logistic regression was used to
estimate odds ratios (OR) and 95 % confidence intervals for the association between MetS and prostate cancer risk.
Results: A history of MetS (≥3 components vs <3) was associated with a reduced risk of prostate cancer (OR = 0.70
[0.60, 0.82]) after considering potential confounders. The negative association was particularly pronounced with a
young age (≤40 years) at MetS onset (OR = 0.38 [0.16-0.89]), did not vary according to prostate cancer
aggressiveness, and was only partly explained by the presence of type 2 diabetes. A risk decrease was observed
with the number of MetS components, suggesting a synergistic interaction of the components.
Discussion: The observed negative association, consistent with results from other North American
populations undergoing regular prostate cancer screening, underlines the importance of considering PSA-testing
when studying the MetS-prostate cancer association.
Conclusions: Findings from this study are consistent with an inverse association between MetS and prostate cancer risk.
Keywords: Metabolic syndrome, Prostate cancer, Case–control studies, Epidemiology, Risk factors
Background
Prostate cancer (PCa) is the most frequent non-skin can-
cer diagnosed in men in the western world [1]. The only
established risk factors (age, family history of PCa and an-
cestry) are not modifiable [2]. Evidence from migration
studies provide support for a role of environmental factors
in PCa etiology [3]. Parallel increases in rates of PCa and
metabolic disorders in North America suggest that factors
associated with westernization, such as diet and physical
activity, may be involved in PCa carcinogenicity [4, 5].
Metabolic syndrome (MetS), defined as a cluster of
metabolic disorders associated with insulin resistance and
visceral adiposity, was first used to identify subjects at in-
creased risk of type 2 diabetes (T2D) and cardiovascular
diseases. Different definitions of MetS have been proposed
since 1998, varying from a glucocentric definition to an
obesity-centric one, but all including glucose intolerance
(high fasting glucose blood level), dyslipidemia (high tri-
glycerides [TG] or low high-density lipoprotein choles-
terol [HDL-C] blood levels), hypertension and abdominal
obesity [6, 7]. MetS represents a growing public health
concern given its high prevalence worldwide [8], especially
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in the United States where one third of the adult popula-
tion is currently affected [4, 9].
MetS is suspected to influence the regulation of PCa
growth and progression through various pathways, includ-
ing the IGF-1 pathway stimulated by hyperinsulinemia,
the sex steroid pathway (increased estradiol, decreased sex
hormone-binding globulin and lower testosterone levels)
and inflammation mediated by cytokines and hormones
produced by adipocytes [10–13]. Although inter-related,
MetS components affect PCa risk differently when consid-
ered separately. For instance, obesity assessed using the
body mass index (BMI) is associated with an increased
risk of high-grade PCa, but data remain insufficient re-
garding the specific role of abdominal fat [14–18]. Long-
standing diabetes is associated with decreased incidence
of PCa [19, 20]. Thus, metabolic disorders have to be con-
sidered together when evaluating their relation with PCa
in order to provide useful guidelines for the management
of PCa risk by physicians [21].
Recent investigations integrating multiple MetS compo-
nents into a single condition have shown positive, negative
or no relationship with PCa risk [10, 22, 23]. Studies have
usually relied on MetS status at study baseline, precluding
the evaluation of MetS timing in relation to PCa, which
may be of importance for a disease with a long natural his-
tory such as PCa. We provide here new evidence for the
association between MetS and PCa, using data from a
large Canadian population-based case–control study.
Methods
Study population
The Prostate Cancer & Environment Study (PROtEuS),
described previously [24–27], is a population-based case–
control study conducted in Montreal, Canada, to assess
the role of environmental factors in PCa risk. Eligible sub-
jects were men, younger than 76 years of age at the time
of diagnosis or selection, residents of the greater Montreal
area, registered on Quebec’s permanent electoral list
(continually updated) and Canadian citizens.
Cases were all patients newly diagnosed with primary
histologically confirmed PCa, actively ascertained through
pathology departments across seven French hospitals in
the Montreal area between 2005 and 2009. This covered
over 80 % of all PCa cases diagnosed in the region of
Montreal during the study period according to registry in-
formation. Concurrent to case recruitment, controls were
randomly selected from the electoral list of French-
speaking men residing in the same districts as cases and
frequency-matched to cases in 5-year age groups.
Study participants represented 79.4 % of eligible cases
and 55.5 % of eligible controls. This study was approved
by the Ethics Committees of the following institutions:
Institut national de la recherche scientifique, Centre de
Recherche du Centre Hospitalier de l’Université de
Montréal, Hôpital Maisonneuve-Rosemont, Hôpital Jean-
Talon, Hôpital Fleury, and Hôpital Charles-LeMoyne. All
participants provided written informed consent.
Data collection
MetS diagnosis was assigned in a similar fashion among
cases and controls, based on the information from the
questionnaire. During face-to-face interviews, subjects
provided the following information: socio-demographic
and anthropometric characteristics (including height and
weight at different ages), family history of cancer, and
PCa screening history. They were also asked to report
any medical condition lasting at least 6 months, includ-
ing diabetes, hypertension and benign prostate hyperpla-
sia (BPH), and medications taken to treat them, with
ages at beginning and end, and duration. Information
was collected about lifestyle factors such as physical ac-
tivity at home, work and leisure, smoking habits, alcohol
consumption and dietary habits. Hip and waist circum-
ferences (WC) were measured by the interviewer. The
degree of aggressiveness of PCa, defined by the Gleason
score, was extracted from prostate biopsy pathology re-
ports and the pre-biopsy prostate specific antigen (PSA)
level at diagnosis from patient files.
MetS definition
We assessed the presence of a MetS history according to
definitions from three organizations: the Adult Treatment
Panel III from the National Cholesterol Education
Program (NCEP-ATPIII) revised by the American Heart
Association / National Heart, Lung and Blood Institute,
the World Health Organization (WHO) and the Inter-
national Diabetes Federation (IDF) [6] (Table 1). The
prevalence of MetS components (diabetes, hypertension,
dyslipidemia and abdominal obesity) was estimated at
2 years before the index date (diagnosis for cases/inter-
view for controls) or at interview for WC-based obesity,
and at different ages (20, 40, 50 and 60 years). The timing
of MetS onset was based on the first concomitant pres-
ence of three individual components. Overall, 1.1 % of
cases and 0.8 % of controls whose information about
metabolic disorders was not sufficient to conclude about
MetS presence were excluded from analyses.
Blood pressure, fasting glucose, TG and HDL-C blood
levels were not available from the study. We used there-
fore medical histories of hypertension, diabetes and dys-
lipidemia (hypercholesterolemia, hypertriglyceridemia,
or intake of the following lipid lowering drugs: statins,
niacin, fibrates, resins or ezetimib). Diabetic subjects re-
ceiving insulin therapy since diabetes onset, who never
took oral anti-diabetic drugs, were considered not to
have T2D. Central obesity was defined on the basis of
BMI or WC according to the MetS definitions consid-
ered (Table 1). As the appropriate WC cutoff for
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abdominal obesity may vary by ethnic origin, we also
used the waist-to-height ratio (i.e., the Index of Central
Obesity: ICO) which has been shown to be more effect-
ive in assessing abdominal obesity across ethnicities with
a simple cutoff [28]. In sensitivity analyses, we used the
NCEP-ATPIII MetS definition which corresponds to the
most recent harmonized definition and includes the WC
cutoff of 102 cm for abdominal obesity recommended
by Health Canada [7].
Statistical analyses
Unconditional logistic regression was used to determine
the risk of PCa associated with MetS. We also assessed
the risk of PCa according to age at MetS first onset
(≤40, 41–50, 51–60 and > 60 yrs), and according to the
number of MetS components.
Risks of low-grade (Gleason scores <7 or 3 + 4) and
high-grade (Gleason scores >7 or 4 + 3) PCa [29] were es-
timated in polynomial logistic models, and their respective
regression coefficients were compared using a Wald test.
All regression models were systematically adjusted for
age (continuous), ancestry (European/Sub-Saharan African/
Asian/Greater Middle East/Other/Don’t know), first-degree
family history of PCa (Yes/No/Do not know) and recent
PSA or Digital Rectal Examination (DRE) screening (No/
≤2 years/>2 years/Do not know). The other covariates
tested were family income (<$C30 000/$C30 000–79 999/
$C80 000 and more/Preferred not to respond/Do not
know), education (Primary or secondary/College or
university), BPH (Yes/No), ever use of aspirin or 5-alpha-
reductase inhibitors (Yes/No), smoking (cigarette pack-
years), alcohol consumption (drink-years), physical activity
(Very/Moderately/Not very active), dietary habits (annual
frequency of fruits and vegetables intake), and changes in
fat or sweets intake in the last 20 years (More/Less/No
change). Variables retained in the final regression model
were those which, when excluded, increased the Akaike
Information Criterion by at least 5.
Sensitivity analyses
The association between MetS and PCa was examined
separately in two age groups (<65 vs. ≥65 year-old at
index date) to investigate the potential competing risk
represented by cardiovascular causes of death, which
would be expected to be less common in the younger
age group.
An analysis was performed restricting subjects to those
screened for PCa (PSA or DRE) within two years of the
index date, thereby limiting the inclusion of controls
with a potentially undiagnosed PCa. We also ran an ana-
lysis restricted to subjects screened with DRE in the last
five years, to evaluate the impact on our results of a po-
tentially lower sensitivity of PSA screening due to de-
creased PSA levels among MetS subjects [30, 31].
We investigated the contribution of T2D in the PCa
risk associated with MetS. We examined whether the as-
sociation between PCa and MetS was different among
subjects of Sub-Saharan ancestry.
The risk associated with each component was estimated
in a multivariate model including other components.
Table 1 Criteria, case–control distribution and association between MetS and PCa, according to different MetS definitions
MetS
Definition
Criteria used in the study Cases (N = 1937) Controls (N = 1995) ORa CI 95 %
N % n %
NCEP-ATPIII At least 3 of these conditions: 476 24.9 629 31.8 0.70 0.60-0.82
- Dyslipidemia (counting for 2 conditions: low HDL-C and high TG)
- Type 2 diabetes
- Hypertension
- WC > 102 cm (or BMI > 30)
NCEP-ATPIII ico NCEP-ATPIII criteria with waist-to-height ratio > 0.5 instead of WC > 102 cm 579 30.3 734 37.2 0.71 0.61-0.82
WHO Type 2 diabetes + 2 other conditions among them: 149 7.8 279 14.1 0.54 0.44-0.68
- Hypertension
- BMI > 30 or waist-to-hip ratio > 0.9
- Dyslipidemia (as a simple condition)
IDF - WC > 90 cm for Asiatic men and > 94 cm for others (or BMI > 30) + 2 other
conditions among them:
427 22.3 527 26.6 0.75 0.64-0.88
- Type 2 diabetes
- Hypertension
- Dyslipidemia (counting for 2 conditions: low HDL-C and high TG)
aAdjusted for age, family history of prostate cancer, ancestry, prostate cancer screening and family income.BMI, Body mass index; CI, Confidence interval; HDL-C,
High-density lipoprotein cholesterol; IDF, International Diabetes Federation; NCEP-ATPIII, Adult Treatment Panel III from the National Cholesterol Education Pro-
gram; OR, Odds ratio; TG: Triglycerides; WC, Waist circumference; WHO: World Health Organization
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Finally, we assessed whether changes in ORs associated
with diabetes and dyslipidemia occurred after adding met-
formin and statin use (yes/no) in the model.
All analyses were performed using SAS software (9.3;
SAS Institute Inc., Cary, NC, USA). A two-sided P value
less than 0.05 was considered statistically significant.
Results
The study population comprised 1937 cases (including
532 high-grade PCa) and 1995 controls. For 3.1 % of
cases and 3.9 % of controls interviews were conducted
with a proxy, usually the spouse.
Cases were slightly younger than controls (Table 2,
p < 0.01). As expected, cases were more likely than con-
trols to have a family history of PCa (p < 0.01), to be of
Sub-Saharan ancestry (p < 0.01) and to have been screened
for PCa in the last two years (p < 0.01). They were less
likely to be of Greater Middle East (p < 0.01) or Asian an-
cestry (p < 0.01). A regular PCa screening (≥ 5 tests during
the previous five years) was more often reported by low-
grade than by high-grade cases (59.2 % vs 50.4 %, respect-
ively, p < 0.01). Cases and controls were similar in terms
of education, fruit and vegetable consumption, smoking
habits and alcohol consumption. Cases had been more
physically active than controls during adulthood (ptrend =
0.06). Cases had a slightly lower BMI than controls (mean
of 26.8 vs 27.2 kg/m2, p < 0.01), but had a similar waist
circumference (98.6 vs 98.5 cm). Dyslipidemia (29.7 %
among cases vs 36.4 % among controls, p < 0.01), hyper-
tension (37.9 % vs 42.3 %, p < 0.01) and T2D (10.6 % vs
17.4 %, p < 0.01) were less frequent among cases, espe-
cially when diabetes was diagnosed more than four years
before the index date or treated with metformin. Statins
and 5-alpha reductase inhibitors uses were similar among
cases and controls, whereas aspirin use was more frequent
among controls (p = 0.04).
Overall, 28.4 % of subjects (24.9 % of cases, 31.8 % of
controls) ever met MetS criteria according to the NCEP-
ATPIII definition (33.8 % if considering the waist-to-
height ratio), 11.0 % according to the WHO definition and
24.5 % according to the IDF definition (Table 1). Most
subjects with MetS as defined by NCEP-ATPIII had a his-
tory of dyslipidemia (94.1 %), hypertension (80.7 %) and/
or abdominal obesity (61.0 %), and 35.0 % had a T2D. The
MetS profile was different among subjects of Sub-Saharan
ancestry, with a higher proportion of T2D (53.9 %) and a
lower proportion of dyslipidemia (71.8 %). Among con-
trols, screening in the last two years was more frequent in
subjects with MetS than in subjects without MetS (85.9 %
vs 74.4 %, p < 0.01), while a history of prostate biopsy was
reported in similar proportions (9.4 % vs 8.0 %, p = 0.32).
Among cases, median PSA levels did not differ according
to the presence or absence of MetS at diagnosis (MetS:
6.0 ng/mL, no MetS: 5.8 ng/mL, pWilcoxon = 0.12).
After adjustment for age, family history of PCa, ances-
try, PCa screening and family income, subjects with a
history of MetS (≥3 components according to the
NCEP-ATPIII definition) were at significantly lower risk
of PCa (OR = 0.70 [0.60-0.82]) as compared to subjects
with fewer than three MetS components. The ORs did
not vary significantly according to PCa aggressiveness
(low-grade: OR = 0.69 [0.58-0.82], high-grade: OR = 0.75
[0.60-0.94]).
In a multivariate model including all the components of
MetS together and the same controlling factors as
previously, a history of abdominal obesity (OR = 1.09
[0.94-1.27]) or hypertension (OR = 0.93 [0.79-1.08]) were
not associated with PCa, but subjects with a history of
type 2 diabetes (OR = 0.66 [0.53-0.81]) or dyslipidemia
(OR = 0.74 [0.63- 0.86]) were still at decreased risk of PCa.
The negative association observed between dyslipidemia
and PCa was stronger when adding statins use in the
model (OR = 0.58 [0.47-0.71]). Once adjusted on metfor-
min use, the risk associated with T2D was reduced, al-
though no longer significantly (OR = 0.78 [0.59-1.05]).
The statistically inverse association between a history
of MetS and PCa was also observed when using other
definitions for MetS or abdominal obesity, with ORs
ranging from 0.54 [0.44-0.68] (WHO) to 0.75 [0.64-0.88]
(IDF) (Table 1). The negative association tended to be
more pronounced among men younger than 40 years at
MetS onset (Fig. 1) and among men diagnosed with PCa
before age 65 (Table 3). Odds ratios were similar when
considering a history of MetS or MetS prevalence at a
given time (or age) (data not shown). Using subjects
with no MetS component as the referent category did
not change the results (data not shown). The risk de-
creased with the number of MetS components present
(Fig. 2, p trend <0.01). This risk decrease was not linear,
suggesting rather a synergistic interaction of MetS com-
ponents under a multiplicative model.
While BPH was positively associated with MetS and
PCa, adjusting for BPH did not change the OR associ-
ated with MetS. Similar results were observed after ex-
clusion of subjects with T2D, of subjects not screened
for PCa in the last two years, or never screened with
DRE in the last five years (Table 3). Odds ratios were of
the same magnitude among the 217 subjects of Sub-
Saharan ancestry as compared to others.
Discussion
In this population-based case–control study including
some 4,000 subjects, we observed a significant inverse
relationship between MetS and PCa, regardless of the
criteria used to define MetS. This negative association
did not vary according to PCa aggressiveness, and was par-
ticularly pronounced when MetS was developed at a young
age (≤40 years). The analysis of the risk according to the
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Table 2 Characteristics of the PROtEuS study population, Montreal, Canada, 2005-2011
Characteristics Cases (N = 1937) Controls (N = 1995)
n % n %
Age at index date
<65 years 1009 52.1 896 44.9
≥65 years 928 47.9 1099 55.1
Ancestry
European 1696 87.6 1686 84.6
Sub-Saharan 130 6.7 90 4.5
Asian 24 1.2 73 3.7
Greater Middle East 45 2.3 99 5.0
Other (Hispanics, Autochtones) 29 1.5 31 1.6
Do not know 12 0.3 14 0.7
Last prostate cancer screening (PSA and/or DRE)
No 3 0.2 191 9.6
≤2 yrs before index date 1917 99.0 1511 75.7
>2 yrs before index date 1 0.1 235 11.8
Do not know 16 0.8 58 2.9
First-degree family history of prostate cancer
No 1419 73.3 1739 87.2
Yes 452 23.3 199 10.0
Don't know 66 3.4 57 2.9
Annual family income
<$C10 000–29 999 490 25.3 497 25.0
$C30 000–79 999 874 45.1 872 43.8
$C80 000- > $C100 000 426 22.0 428 21.5
Preferred not to responda 132 6.8 186 9.3
Do not know 15 0.8 9 0.4
Education
Primary 449 23.2 429 21.5
Secondary/College 891 46.1 953 47.8
University 592 30.6 611 30.7
Physical activityb
Not very active 444 22.9 503 25.2
Moderately active 518 26.8 545 27.3
Very active 974 50.3 946 47.4
Daily frequency of fruits and vegetables consumptionc
≤6 477 24.8 498 25.0
]6-9] 507 26.3 497 25.0
]9-12] 431 22.4 497 25.0
>12 511 26.5 498 25.0
Smoking (pack-years), mean ± SD 22.3 ±27.1 23.6 ±27.3
Alcohol intake (drink-years), mean ± SD 75.2 ±121.6 73.8 ±136.6
Body Mass Index 2 yrs ago (kg/m2), mean ± SD 26.8 ±4.0 27.2 ±4.4
Waist circumference (cm), mean ± SD 98.6 ±13.6 98.5 ±14.3
History of dyslipidemiac 576 29.7 727 36.4
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number of MetS components suggests a dose–response
relationship with MetS severity.
Selection bias
Response rates could have affected results if socioeco-
nomic characteristics associated with MetS influenced
subjects’ participation. However, according to Canadian
census tract data for 2006, the rates for recent immigra-
tion, unemployment, low educational level and low
household income were similar in living areas of partici-
pants and non-participants, both among cases and con-
trols, indicating that selection bias is not of major
concern in the study.
Detection bias
Misclassification of PCa status due to under-detection is
possible in both prospective and case–control studies.
However, the present study is set in a population with
very high PCa screening rates, thereby minimizing
chances of a detection bias. Indeed, as a result of a univer-
sal access to health care in Montreal, study participants
were relatively uniformly and regularly screened for PCa,
whatever their socioeconomic position. However controls
with MetS were more likely to have been screened re-
cently, which may reflect a closer medical follow-up re-
lated to their condition. Nevertheless, this would have
increased the probability of PCa diagnosis among MetS
subjects, leading to underestimate a true negative associ-
ation. Furthermore, the similar results observed in analysis
restricted to subjects recently screened do not support an
important impact of screening frequency on our findings.
Subjects with MetS are known to have decreased PSA
levels [30], which may result in a PCa diagnosis at a
higher stage and/or grade. This could lead to differential
misclassification and overestimation of a negative associ-
ation between MetS and PCa, especially regarding local-
ized and/or low-grade cases. However, our results did
not change substantially when MetS risk was stratified
Table 2 Characteristics of the PROtEuS study population, Montreal, Canada, 2005-2011 (Continued)
Ever use of statin 337 17.4 358 17.9
History of hypertensionc 732 37.9 842 42.3
Type 2 diabetesc 205 10.6 348 17.4
Diagnosed ≥5 years ago 140 7.2 246 12.3
Ever use of Metformin 102 5.3 201 10.1
History of benign prostate hyperplasiac 510 26.3 411 20.6
Ever use of Aspirinc 308 15.9 367 18.4
Ever use of 5α-reductase inhibitorsc 33 1.7 46 2.3
aSubjects who preferred not to answer were more often from the Middle East and had a lowest educational level than others
bTaking into account the reported level of physical activity at home and at work, and the lifetime frequency of leisure activities
cTwo years before diagnosis / interview
DRE, Digital rectal examination; PSA, Prostate specific antigen; SD, Standard deviation
Fig. 1 Odds ratioa for the risk of prostate cancer according to age at metabolic syndromeb onset. aAdjusted for age, family history of prostate
cancer, ancestry, prostate cancer screening and family income. bAccording to the definition of the Adult Treatment Panel III from the National
Cholesterol Education Program with body mass index instead of waist circumference which was only measured at interview
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according to PCa grade. Moreover, the association was
of the same magnitude among subjects recently screened
with DRE, which was shown to improve the predictive
value of PCa screening among obese men [32]. Finally,
controls with MetS were not less likely to have been re-
ferred for prostate biopsy compared to controls without
MetS, and PSA levels among cases did not vary signifi-
cantly according to the presence of MetS at diagnosis.
Taken together, these observations argue against an im-
portant detection bias due to a decreased sensibility of
PSA screening among subjects with MetS.
MetS exposure classification
A recall bias could be suspected in view of the study de-
sign, which would have led to underestimate a negative
association. We were able to check the reliability of self-
reported MetS-related conditions by referring to patient
files in the hospitals where PCas were diagnosed. For re-
spectively 84 %, 94 % and 93 % of cases reporting dyslip-
idemia, diabetes or hypertension at diagnosis, these
disorders were also mentioned in patients’ files, indicat-
ing that ascertainment of individual MetS components
was reasonably valid. With regard to controls, there is
Table 3 Association between metabolic syndromea and prostate cancer risk according to screening, age, ancestry and diabetes
Strata characteristics N ORb 95 % CI
DRE screened in the last five years 3202
All cases 0.70 0.60-0.82
Non aggressive cases 0.68 0.57-0.81
Aggressive cases 0.75 0.60-0.95
Screened during the last two years 3387 0.62 0.50-0.78
Age at diagnosis (cases) / interview (controls)
< 65 years 1892 0.60 0.47-0.76
≥ 65 years 1986 0.79 0.64-0.96
Ancestry
Sub-Saharan 217 0.80 0.36-1.78
Other (including European, Greater Middle East, Asiatic and Latino ancestries) 3650 0.70 0.60-0.82
Type 2 diabetes
No 3340 0.80 0.67-0.96
Yes 551 0.67 0.44-1.01
aAccording to the definition of the Adult Treatment Panel III from the National Cholesterol Education Program
bAdjusted for age, family history of prostate cancer, ancestry, prostate cancer screening 2 years earlier, and family income
CI, Confidence interval; DRE, Digital rectal examination; OR, Odds ratio
Fig. 2 Odds ratioa for the risk of prostate cancer according to number of metabolic syndrome components. aAdjusted for age, family history of
prostate cancer, ancestry, prostate cancer screening and family income. The referent category was represented by subjects without any
metabolic disorder
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little reason to suspect them of having over-reported
MetS-related conditions, thereby driving results towards
a protective association. Furthermore subjects and inter-
viewers were blinded to the hypothesis under study and
metabolic disorders were not the primary focus of the
questionnaire.
Waist circumferences were measured by trained inter-
viewers. While advanced stage PCa can lead to weight
loss, only negligible weight losses were recorded in the
two years preceding index dates. Moreover in contem-
porary newly diagnosed PCa, cancer-related weight loss
is virtually unseen within two years of diagnosis. When
WC was missing, we used the standard threshold for
obesity, i.e., a BMI of 30, rather than a BMI value that
better corresponds to a WC of 102 cm in our data, to fa-
cilitate comparison with previous studies.
Using NCEP-ATPIII criteria, we observed a MetS
prevalence of 22 % and 34 % among controls aged 40–
59 and ≥60 years, respectively. This prevalence was simi-
lar in the younger group but about 20 % lower in the
older one in comparison with that reported in two Can-
adian surveys based on clinical values for blood pressure,
TGs, HDL-C and blood glucose [33, 34]. This may re-
flect a better participation of healthy subjects with lim-
ited cardiovascular risk factors in this age group. Indeed,
MetS is an indicator for cardiovascular disease risk [35],
and competing risk of death from cardiovascular causes
was found to bias the association towards negative
values [36, 37] or the null value [38] in cohort studies,
and may bias the association towards the null value in
case–control studies. According to this, our conclusion
for a negative association was likely in the correct direc-
tion, albeit conservative in terms of magnitude. Besides,
the negative association remained significant, and more
pronounced with a young age at MetS onset, among
subjects aged 65 years and more.
As documented in other investigations [20], T2D was
less frequent among PCa patients. However, inclusion of
this condition in the MetS definition does not solely ex-
plain the inverse relationship observed. The prevalence
of diabetes was low compared to other components
(35 % of the subjects with MetS) and the negative associ-
ation with MetS was still significant after adjustment for
diabetes or exclusion of diabetic subjects.
About half of subjects with a history of dyslipidemia
ever took statins. Statins use has been shown to be asso-
ciated with a reduced risk of PCa, especially advanced
ones [39]. However, statin intake did not contribute to
the negative association observed with dyslipidemia in
our sensitivity analysis.
Confounding/effect modification
We were able to consider a wide range of potential con-
founders. Lifestyle components, including physical activity
and diet, did not emerge as important confounding factors
in our study population. Subjects of sub-Saharan ancestry
were found to have a distinct MetS profile, as observed
previously in an American population [40]. However the
risk of PCa associated with MetS was similar across
ancestries.
Comparison with previous studies
The literature on the role of MetS in PCa development
is divided. No association was found between MetS and
PCa risk in two recent meta-analyses, one based on 14
studies (RR = 1.12 [0.93-1.35]) [22] and another based on
nine cohort studies (RR = 0.96 [0.85-1.09]) [23]. How-
ever, there was a trend for a positive relation between
MetS and PCa aggressiveness among PCa patients in an-
other meta-analysis including seven studies (high grade
PCa: OR = 1.36 [0.90-2.06], advanced PCa: OR = 1.37
[1.12-1.68]) [23]
The conflicting findings across studies may relate to dif-
ferences in PCa detection practices between populations.
Positive associations were more often observed in Europe
[41–44], whereas negative associations, such as ours, were
found in North America [45, 46], except among African
Americans [40, 47]. This trend might be explained by a
less frequent systematic PCa screening in Europe [48],
where studies have observed a globally more aggressive
cancer profile. Supporting evidence comes from a recent
Swedish prospective cohort, using a composite score com-
bining z scores of MetS components [49]. No association
was observed with overall risk of PCa, while a positive as-
sociation emerged for PCa mortality. However, in analyses
restricted to cases diagnosed since 1997, the MetS score
was significantly associated with a decreased PCa risk.
This period was characterized by an increase in low-grade
PCa incidence due to more frequent PSA testing. In a
more recent analysis taking into account competing
events, the decrease in PCa risk observed among men
with metabolic disorders was more pronounced in the
PSA era [38].
Even when stratified on PCa aggressiveness, results ob-
served in highly screened populations cannot be inter-
preted in the same way as in other populations. The PCa
grade captured at the time of diagnosis depends on
screening practices and does not take into account the
whole history of PCa progression. For instance, the ob-
served association between MetS and aggressive PCa [42,
50, 51] may ensue from delayed detection among subjects
with MetS. Besides, non-screened controls may include
non-detected cases, directly impacting case ascertainment.
Other reasons may explain discrepant findings across
studies. Two studies and a multicenter clinical trial have
been conducted on Spanish [51], Canadian [52] and
worldwide [53] patients referred for prostate biopsy.
They observed an increased risk of high-grade PCa with
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MetS, but either no association or a positive one was
found with overall PCa risk. In the three studies, PSA
levels were elevated among participants [51–53], and the
prevalence of MetS was low in the clinical trial [53]. It is
thus unclear how findings based on biopsy series compare
to those from population-based studies, since exclusion of
asymptomatic and untested subjects from control series
may have compromised representativeness to the popula-
tion base, including with respect to MetS prevalence.
Previous investigations have applied different MetS
definitions. Interestingly, the four studies that used
the NCEP-ATP III MetS criteria with a WC of
102 cm for abdominal obesity and that considered
subjects with less than three MetS components as the
reference group [46, 50, 51, 54] observed, like us, an
inverse association between MetS and PCa risk. While
using different MetS definitions did not substantially
alter our own findings, it may not be so when apply-
ing different criteria to populations presenting diverse
anthropometric or clinical patterns.
Finally, methodological issues may be at play. Most previ-
ous studies were based on limited numbers of exposed
cases. Our study was especially well-powered with some
2000 cases, almost 500 of whom having MetS. Three other
recent powerful studies, with more than 300 exposed cases,
were recently published on this topic, but these did not
consider potential confounding by socioeconomic status,
medical history (comorbidities, medication) and/or lifestyle
[49, 51, 52]. In another study using a questionnaire-based
MetS assessment similar to ours, and reporting a positive
association especially in low-grade cases [43], selection (or
classification) biases can be suspected in view of the very
low MetS prevalence and of socioeconomic differences be-
tween cases and hospitalized controls.
One salient advantage of this study is its ability to inves-
tigate the role of age at MetS onset in PCa risk which, to
our knowledge, has never been investigated. Using a retro-
spective approach, we could trace the MetS history all
along the potential period of PCa development. About half
of our subjects with MetS had developed it after age 60.
Prospective cohorts have typically relied on a single MetS
assessment at baseline including participants of different
ages [36, 42, 45, 49, 52, 54, 55], or possibly too young to
capture an eventual occurrence of MetS during adulthood
[41, 42]. We observed a stronger risk decrease with a
young age at MetS onset. In a cohort of men aged 40–49
years, MetS defined using NCEP values was not predictive
of PCa [41]. However diabetics, which account for 18 % of
our subjects with prevalent MetS at age 40, were excluded
from this former cohort.
Potential mechanisms
Biological pathways involving low insulin, IGF-1 and tes-
tosterone levels have been suggested to explain a negative
association between MetS and PCa [13]. The pronounced
negative association observed with a young age at MetS
onset may relate to the timing of diabetes occurrence. In-
deed, a reduced risk of PCa is usually observed only sev-
eral years after diabetes diagnosis [56], probably because
long-standing diabetics may experience low insulin levels
in later years. Besides, the apparent contribution of dyslip-
idemia to the negative association observed raises the
issue of the role of cholesterol in prostate malignancy,
although some evidence suggests that it might be posi-
tively related with PCa growth [57–60]. Conversely, a
cholesterol-lowering effect of cancer has been suggested,
as a result of tumor metabolism. Low cholesterol-cancer
associations have been mostly observed in studies con-
ducted before introduction of PSA-testing, including more
advanced PCas, or in PSA-screened populations where
cholesterol was measured within one year of cancer diag-
nosis [61]. The high PSA-screening rate in our population
and our application of a two-year-lag in the analysis be-
tween MetS assessment and PCa diagnosis do not support
such a reverse relation. Future experimental research ex-
ploring potential biological mechanisms of MetS should
consider the synergistic interaction of MetS components.
Conclusion
Our findings provide evidence for a negative association
between a history of MetS and PCa risk in a population
regularly screened for PCa.
These findings can be interpreted in two ways. First,
while it likely had a marginal influence on our results,
under-detection of PCa among MetS patients remains
possible. This issue should be addressed in future epi-
demiological studies. Second, a synergistic interaction
between metabolic factors can be at play, with diabetes
and dyslipidemia as main actors.
Large studies including repeated biological measure-
ments over time are required to confirm the role of tim-
ing at MetS onset on PCa development.
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